Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT 02628067 Brief Summary In this study, participants with multiple types of…
Read more arrow_forwardNCT 02628067 Brief Summary In this study, participants with multiple types of…
Read more arrow_forwardNCT 03821935 Brief Summary The study will determine the recommended Phase 2…
Read more arrow_forwardNCT 04665206 Brief Summary This is an open-label, dose escalation and expansion…
Read more arrow_forwardNCT 04585750 Brief Summary The Phase 2 monotherapy portion of this…
Read more arrow_forwardNCT 06003621 Brief Summary This phase II study will explore the effect…
Read more arrow_forwardNCT 05356741 Brief Summary This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation…
Read more arrow_forwardNCT 04589845 Brief Summary TAPISTRY is a Phase II, global, multicenter, open-label,…
Read more arrow_forward